First-in-human study of ¹⁷⁷Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

Purpose

This translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of ¹⁷⁷Lu-EB-PSMA-617 in comparison to ¹⁷⁷Lu-PSMA-617 in patients with mCRPC.

Methods

Following institutional review board approval and informed consent, nine patients with mCRPC were recruited. Four patients accepted intravenous injection of 0.80-1.1 GBq (21.5-30 mCi) of ¹⁷⁷Lu-EB-PSMA-617, then underwent serial whole-body planar and SPECT/CT imaging at 2, 24, 72, 120 and 168 h. The other five patients accepted intravenous injection of 1.30-1.42 GBq (35-38.4 mCi) ¹⁷⁷Lu-PSMA-617, then underwent the same imaging procedures at 0.5, 2, 24, 48, and 72 h. All patients were evaluated by ⁶⁸Ga-PSMA-617 PET/CT

SUBMITTER: Zang J 

PROVIDER: S-EPMC6250576 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature